TradingMenu expanded
Forge Markets Forge Pro Browse Companies
DataMenu expanded
Forge Data Private Market Index Forge Accuidity Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News Tech IPO Calendar for 2024
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Forge Pro
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
Forge Accuidity Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
Tech IPO Calendar for 2024
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / TriSalus Life Sciences Stock

TriSalus Life Sciences Stock

trisaluslifesci.comHealthcare / BioTech & PharmaFounded: 2009Funding to Date: $198.81MM

TriSalus Life Sciences is a biopharma company that specializes in treatment research and development for tumors of the liver and pancreas. TriSalus involves a team of clinicians and scientists who develop systemic immunotherapies to fight tumors through its developed drug delivery methods.

Learn more about TriSalus Life Sciences IPO

Register To Buy and Sell Shares

For more details on financing and valuation for TriSalus Life Sciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access TriSalus Life Sciences’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like TriSalus Life Sciences.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Mary Szela
Chief Executive Officer and President
Steven C. Katz, MD, FACS
Chief Medical Officer, Scientific Advisory Board Chairman
Sean Murphy
Chief Financial Officer
Trevor McCaw
Chief Commercial Officer
Bryan F. Cox, PhD
Chief of Research
Jennifer L. Stevens, JD
Chief Regulatory Officer
Richard B. Marshak VMD, MBA
Business Development & Strategy, SVP

Board Members

Beverly Huss
Vibrynt
Sean Murphy
Malin Corporation
John Tullis
Tullis Health Partners
Norman Weldon
Partison Management Group
Karen Cassidy
Partisan Management Group
Mark T. Lupa
High Country Venture
Ginger Graham
Independent Director
Mats Wahlstrom
KMG Capital Partners

Other companies like TriSalus Life Sciences in the BioTech & Pharma sector

Egenesis

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$387.57MM

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Prime Medicine

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.23B

ADARx Pharmaceuticals

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$827.77MM

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$6.33B

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.7B

Pendulum Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$308.05MM

Cytonics

Sector
Healthcare / BioTech & Pharma
 
 

AI Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM

News Highlights

Pharmaceutical Technology 08/11/2023
TriSalus merges with MedTech Acquisition to bolster cash reserves
TriSalus Life Sciences has merged with MedTech Acquisition Corporation to increase their cash reserves and fund developmental and commercial milestones. The merged company will trade on Nasdaq under the symbols "TLSI" and "TLSIW". The merger is expected to provide a cash runway until mid-2024 to support various plans, including the development of a cancer therapy.

Trending Companies

Frequently Asked Questions

Updated on: Apr 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.